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ABSTRACT Atopic dermatitis is a common term used in the medical literature, 
but according to The Nomenclature Review Committee Of The World Allergy Or-
ganization the name which should be used is eczema. Eczema is divided into two 
subtypes: atopic and non-atopic. These subtypes differ in the level of total immu-
noglobulin E (IgE) in serum, response to allergens in skin prick tests, and detec-
tion of specific IgE antibodies. Non-atopic eczema is characterized by a low level 
of total IgE, negative skin prick tests, and undetectable specific IgE antibodies. It 
is estimated that 10-45% cases of eczema are non-atopic ones. In recent studies, 
other features differentiating these two subtypes have been identified, such as fe-
male predominance in non-atopic eczema. A more severe course, damage of the 
epidermal barrier, predominance of Th2 (T helper cells 2) response, and a lower 
positive reaction to metal patch tests are the characteristics of the atopic subtype. 
In our opinion, new diagnostic criteria taking into account the non-atopic subtype 
of eczema need to be established.
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INTRODUCTION
Atopic dermatitis is a chronic and relapsing skin 
inflammatory disease with characteristic morphol-
ogy and skin lesions that usually begins during early 
childhood. The occurrence of atopic dermatitis is esti-
mated at 15-30% in children and 2-10% in adults. Dur-
ing the last 3 decades, the incidence of this disease in 
developed countries has doubled or even tripled (1).
In order to standardize the diagnosis of atopic der-
matitis in the last decades, some diagnostic criteria 
have been added. In 1980, Hanifin and Rajka intro-
duced a procedure which is based on 4 major and 27 
minor criteria. One of the major criteria is the atopic 
history of the patient and/or family members, whereas 
a minor criterion indicates increased immunoglobulin 
E (IgE) serum levels (2). The UK criteria, introduced in 
1994, significantly reduced the number of Hanifin and 
Rajka’s criteria and are mainly based on the personal 
atopic history and clinical features (3). In 1998, the Mil-
lennium criteria, which contain the required identifi-
cation of specific IgE, were presented (4). 
The term atopic dermatitis is commonly used in the 
medical literature despite the fact that The Nomencla-
ture Review Committee Of The World Allergy Organi-
zation in 2003 recommended that the name eczema 
be used instead. Atopic eczema (AE) was identified as 
an IgE-dependent disease of genetic origin. Its diag-
nosis is established by skin prick tests or detection of 
specific IgE from serum (5). AE meets the definition of 
atopy as a personal and/or familial tendency, usually in 
childhood or adolescence, to become sensitized and 
produce IgE antibodies in response to ordinary expo-
sures to allergens, usually proteins. As a consequence, 
these patients can develop typical symptoms of asth-
ma, rhinoconjunctivitis, or eczema (5). However, there 
is a group of patients with similar clinical features as in 
atopic eczema but with no detectable sensitization to 
airborne or food allergens and whose total IgE serum 
level is not increased. The Nomenclature Review Com-
mittee of the World Allergy Organization defines it as 
non-atopic eczema (nAE) (5).
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Various terms for nAE can be found in literature, 
such as: atopiform dermatitis, non-allergic atopic der-
matitis, intrinsic atopic dermatitis, the syndrome of 
non-allergic atopic eczema/dermatitis, the syndrome 
associated with T-cell atopic eczema/dermatitis (T-
cell associated AEDS) (5-8).
nAE can occur in 10-45% of patients with eczema, 
and the latest studies point to 27% (9), 37% (10), 12% 
(6), and 22% (11).
Differences Between nAE and AE
In recent years, many clinical studies related to explo-
ration of the differences between these two subtypes of 
eczema have been published (6,9-26) (Table 1).
As far as age is concerned, a higher percentage of 
patients with nAE has been assessed in younger pop-
ulations with eczema (6,10). Kusel et al. found one-
third of patients with nAE in a pediatric population 
with eczema (14). Folster-Holst et al. assessed that cas-
es of nAE in adult population were at 6.9% (11). Con-
cerning the sex of eczema patients, female predomi-
nance in nAD was widely noticeable (7,11,15,16,26). 
However, Roguedas-Contios et al. pointed out female 
predominance in both subtypes of eczema (8).
Some studies have indicated a more severe course 
of the disease in patients with AE on the basis of SCO-
RAD (scoring atopic dermatitis) and stronger itching 
sensations using VAS (visual analogue scale) (15-18). 
One study, which was based on SCORAD, also found 
more severe disease in patients with AE. Yet, based on 
EASI (eczema area and severity index), there was no 
statistical difference in the disease severity between 
the groups (6).
Correlations between increased IgE level or el-
evated levels of Th2 cytokines and escalation of the 
disease severity (SCORAD) were found in AE. More-
over, a correlation between the severity of skin le-
sions and elevated levels of Th1 cytokines and IL17 in 
nAE was discovered (19).
Interestingly, patients with AE used external ste-
roid medications, calcineurin inhibitors, antihista-
mine drugs, and emollients more frequently. Addi-
tionally, their quality of life was estimated as worse 
than that of the patients with nAE. The relationship 
between disease severity and the course of disease 
dependent on stress and environmental factors was 
less noticeable in patients with nAE (6).




• age of the population younger elder
• gender predominance female no/male
• frequency 10-45% 55-90%
Pathophysiology
• immune response Th1 Th2
• infiltration of Th17 and Th 22 high low
• specific IgE antibodies to food and airborne allergens - +
• increased level of IgE receptors on monocytes and dendritic cells - +
• level of total IgE normal elevated
• skin prick tests to food and airborne allergens negative positive
• positive patch tests for metals frequent rare
• filaggrin mutations very rare frequent
• TEWL (transepidermal water loss) normal increase
• skin moisture sufficient insufficient
Clinical features
• atopic family history rare frequent
• associated atopic diseases very rare frequent
• quality of life  
• itching low high
• non-specific hand or foot eczema + +++
• palmar hyperlinearity + +++
• keratosis pilaris + +++
• pityriasis alba + +++
• Dennie-Morgan’s fold  ++ +
• disease severity + ++
Treatment 





Natural course iAD  eAD 
possible
eAD  iAD ?
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Clinical Features
Most researchers agree that both eczema subtypes 
differ in the frequency of clinical symptoms occur-
rence. The most frequent symptom in nAE was Den-
nie-Morgan’s fold (38.2% vs 19.7% in AE). The features 
which predominated in AE were: palmar hyperlinear-
ity (23.8% vs 2.9% in nAE), keratosis pilaris (22.1% vs 
5.9%), pityriasis alba (77.9% vs 10.0%), and non-spe-
cific hand or foot eczema (31.1% vs 11.8%) (6).
However, different results were obtained by 
Kulthanana et al. in the study performed on a Thai 
population of 56 patients with eczema (12.5% with 
nAE), in which ichthyosis vulgaris and non-specific 
hand and foot eczema occurred more often in pa-
tients with nAE. In addition, the influence of environ-
mental factors and stress on the course of the disease 
was more frequent among patients with nAE (20).
The Skin Barrier
The difference in the skin barrier between the 
two subtypes of eczema has been indicated as well. 
Patients with AE are characterized by a defective 
skin barrier, but nAE patients show no damage to it. 
TEWL (transepidermal water loss) and skin moisture 
research showed lower skin moisture and increased 
TEWL in patients with AE in comparison with healthy 
patients and those with nAE, who showed no dif-
ference (15,21). Furthermore, the loss of filaggrin 
function predisposes to the development of AE and 
asthma. Filaggrin mutations are also associated with 
higher incidences of ichthyosis and palmar hyperlin-
earity (27). Additionally, disorders of the skin barrier 
due to decreased or no filaggrin expression as well as 
enzymatic disorders of the transformation from pro-
filaggrin into filaggrin lead to transdermal penetra-
tion of antigens and their increased exposure to the 
immune system (21,28).
In a Japanese study, the filaggrin gene mutations 
were observed in 3.7% of the population. The study 
revealed a significantly higher percentage of filaggrin 
mutations (8 most frequent mutations in the Japa-
nese population) in patients with AE (9 in 29 patients, 
31%) in comparison with nAE ones (1 in 20 patients, 
5%) (22). Another study on a group of Japanese pa-
tients consisting of 18 subjects with the AE and 19 
subjects with nAE reported that the filaggrin muta-
tion was found in 8 patients (44.4%) and 2 patients 
(10.5%) of each group respectively (16).
The Immune System and Cytokines
Many researchers support the idea that elevated 
total IgE levels in patients with AE is caused by B lym-
phocyte activation due to increased concentration of 
interleukin (IL) 13 and IL4. These interleukins are pro-
duced by T helper (Th) 2 lymphocytes located in the 
skin. Conversely, higher production of INFγ by Th1 
lymphocytes can cause suppression of IgE produc-
tion in patients with nAE (12,16,29,30).
In 2013, Suarez-Farinas et al. defined the types of 
cells in skin lesions of patients with nAE and AE (19). In 
this study, epidermis hyperplasia was similar in both 
subtypes. Both subtypes showed intensive inflamma-
tory infiltration and increased levels of T cells and my-
eloid dendritic cells in comparison with intact skin. 
Additionally, patients with nAE experienced increased 
T-cell infiltration of CD3 and CD8, myeloid dendritic 
cells, Langerhans’s cells, and mature dendritic cells 
in comparison with AE. Less visible differences were 
found in the amount of inflammatory dendritic epi-
dermal cells, residual dendritic, and atopic dendritic 
cells. Interestingly, neutrophils were more numerous 
in the changes of nAE patients while eosinophils and 
plasmocytic dendritic cells were more numerous in 
skin lesions of patients with AE.
Greater inflammatory infiltration has been found 
in patients with nAE. Skin lesions in patients with nAE 
showed higher or equal infiltration, activity of Th1 
and Th2 cells, and much higher infiltration of Th22 
and Th17 cells in comparison with AE (19). These dif-
ferences may indicate the possibility of greater im-
portance of Th22 and Th17 cells in nAE. It has been 
indicated that the enhanced responses of Th1, Th2, 
and Th22 in both eczema subtypes, the lack of an im-
munological shift toward Th2 cells in AE, and propor-
tionally high Th2 activity in nAE mean that the results 
of this study differ from the findings of previous years. 
For this reason, it may be assumed that the regulation 
of IgE secretion is more complex.
The increased level of FOXP3 (forkhead box P3), a 
marker for regulatory T cells, in skin lesions was found 
in a patient with nAE (19) whereas these regulatory 
T cells suppress IgE allergic response and induce im-
munoglobulin G4 (IgG4) response (31).
Another potential mechanism of reducing IgE lev-
els is the elevated level of IL17A. It causes the inhibi-
tion of TSLP (thymic stromal limphopoietin) which is 
produced by dendritic cells. Inhibition of TSLP secre-
tion reduces Th2 response (32).
Furthermore, cathelicidin production was lower 
in patients with AE in comparison with nAE (23). This 
may also be associated with a higher level of IL17 in 
patients with nAE because IL17 production increases 
the production of cathelicidin/IL37. The larger num-
ber of neutrophils in the tissue may also be associ-
ated with the elevated level of Th17 cells/IL17 in pa-
tients with nAE.
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Higher concentrations of IL4, IL5, IL13 cytokines 
were found in the peripheral blood of patients with 
AE, which is typical for Th2 response, whereas nAE 
patients had a lower concentration of IL4 and IL13 
(16,24). Simon et al. found that the two eczema sub-
types had an increased level of IL-5 and IL13 (33). nAE 
is characterized by more Th1 lymphocytes in periph-
eral blood, which causes the increased production 
of IFNγ and a decrease in the amount of B cells and 
IgE production (16,34). Patients with AE have lower 
ability to produce INFγ after stimulation of peripheral 
lymphocytes by antibody CD3 (34).
It was also confirmed that the number of IgE re-
ceptors with high and low affinity (FcεRI and FcεRII/
CD23) and α-chain of the IL4 receptor in monocytes 
significantly increased in patients with AE. IL4 recep-
tors decrease the production of IFNγ by connecting 
IL4 and IL13. In addition, the polymorphism of IL4R-α 
(C3223T) and IL4 (C590T) was higher in patients with 
AE (7). The increase of FcεRI receptor expression in in-
flammatory dendritic cells in skin lesions of patients 
with AE was also confirmed. This observation can be 
considered as one of the diagnostic criteria which 
differentiate between the two subtypes of eczema 
(13,35,36).
Sensitivity to Metals
A damaged skin barrier and transepidermal per-
meation of protein allergens induces a Th2 response, 
but Th1 cells are induced by non-protein allergens 
such as metals. The mechanism that causes polariza-
tion in the direction of Th1 reaction on haptens of 
metals is not fully understood. Nickel (Ni) and cobalt 
(Co) may be presented by the MHC (major histocom-
patibility complex), and TLR4 (toll-like receptor 4) re-
ceptors also react with antigen-presenting cells such 
as dendritic cells (37,38). High percentage of positive 
patch tests for metals has been reported in patients 
with eczema, with no division into subtypes (34). In 
patients with nAE who have an undamaged skin bar-
rier, there is no protein permeation into the skin and 
no Th2 response inducement. However, metals can 
penetrate through undamaged skin which can in-
duce Th1 response.
In a study of 137 children with eczema, 19.3% of 
patients were positive in metal patch tests (39). The 
study confirmed that Ni, Co, and chrome (Cr) are the 
three main metals allergies most frequently detected 
in the population with eczema (25). The analysis of al-
lergies to Ni, Co, and Cr in 86 patients with eczema 
gave positive results in 25.6%, 20.9%, and 16.3% pa-
tients, respectively. Patients with nAE showed a sig-
nificantly higher percentage of positive reactions to 
metals than patient with AE: Ni: 41.9% vs 16.4%; Co: 
38.7% vs 10.9%; Cr: 22.6% vs 12.7%, respectively. Gen-
erally, positive results to these metals were at 61.3% 
for nAE (19/31) and 25.5% for AE (14/55). Additionally, 
higher concentrations of Ni and Co in the sweat were 
found in patients with nAE. This may indicate that al-
lergy to metals is one of the factors in the develop-
ment of nAE (37,38).
Possibilities of Transmission Between nAE 
and AE
In a study of 56 patients initially diagnosed as nAE, 
18 of them developed specific IgE in a few years’ time 
(6). Folster-Holst et al. noticed a decrease in the num-
ber of patients with nAE in an adult population over a 
period of 7.5 years from 6.8% to 5.4% because of the 
detection of inhaled allergies (11). By comparing the 
age of the patients, a higher percentage of patients 
with nAE was found in the younger population of 
patients with eczema (10). This may indicate a shift 
from nAE to AE over time, as can be evidenced from 
the smaller percentage of patients with nAE in adult 
populations of eczema patients.
This indicated that the tests for a level of total IgE, 
specific IgE, and prick tests should be repeated after a 
period of several years in order to differentiate these 
two types of eczema if the previous results were 
negative. Additionally, the tests for specific IgE can-
not be sufficiently specific. Patients can be sensitive 
to inhaled or food allergens which are not examined 
in routine tests. They can also be allergic to S. aureus 
antigens, Malassezia sympodialis, or other allergens. 
Tokura described IgE antibodies against Malassezia 
sympodialis in patients with AE and nAE, however, 
according him, those antibodies should not be taken 
into account in differentiation of eczema subtypes 
(26).
CONClUSION
Based on the relevant research, we can confirm 
that the differences between these two subtypes of 
eczema are not only in the elevated level of total IgE, 
specific IgE detection, or positive skin prick tests, but 
that they are also visible in the clinical picture, skin 
barrier function, and in the number of inflammatory 
cells in the skin.
Yet, is this differentiation really needed and will 
it bring improvement in the patient quality of life? It 
seems that differences in immunological reactions 
are the crucial factors which differentiate between 
these two eczema subtypes. This observation could 
point to a new way for diagnostic tests and new treat-
ment tactics (e.g. use of IL-17, IL-22 antagonists) as 
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well as influence detailed prophylactic recommenda-
tions. On the other hand, it should be remembered 
that nAE could transform into AE, and that general 
prophylactic principles and therapeutic procedures 
should be identical in both subtypes.
In our opinion, new diagnostic criteria which will 
take nAE into account should be introduced. In or-
der to resolve disputes on the pathogenesis and dif-
ferences between these two subtypes of eczema, a 
study on a large group of patients with standardized 
diagnostic criteria and testing methods should be 
conducted.
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